- Home
- XIN vs LPCN Comparison
XIN vs LPCN Comparison
Compare XIN & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XIN
- LPCN
- Stock Information
- Founded
- XIN 1997
- LPCN 1997
- Country
- XIN China
- LPCN United States
- Employees
- XIN N/A
- LPCN N/A
- Industry
- XIN Homebuilding
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- XIN Consumer Discretionary
- LPCN Health Care
- Exchange
- XIN Nasdaq
- LPCN Nasdaq
- Market Cap
- XIN 16.2M
- LPCN 16.4M
- IPO Year
- XIN N/A
- LPCN N/A
- Fundamental
- Price
- XIN $2.62
- LPCN $3.17
- Analyst Decision
- XIN
- LPCN Strong Buy
- Analyst Count
- XIN 0
- LPCN 1
- Target Price
- XIN N/A
- LPCN $10.00
- AVG Volume (30 Days)
- XIN 11.4K
- LPCN 10.5K
- Earning Date
- XIN 01-01-0001
- LPCN 03-13-2025
- Dividend Yield
- XIN N/A
- LPCN N/A
- EPS Growth
- XIN N/A
- LPCN N/A
- EPS
- XIN N/A
- LPCN N/A
- Revenue
- XIN $667,143,185.00
- LPCN $11,198,144.00
- Revenue This Year
- XIN N/A
- LPCN N/A
- Revenue Next Year
- XIN N/A
- LPCN $37.31
- P/E Ratio
- XIN $0.30
- LPCN N/A
- Revenue Growth
- XIN N/A
- LPCN N/A
- 52 Week Low
- XIN $2.24
- LPCN $2.91
- 52 Week High
- XIN $7.05
- LPCN $11.79
- Technical
- Relative Strength Index (RSI)
- XIN 44.57
- LPCN 41.52
- Support Level
- XIN $2.58
- LPCN $3.00
- Resistance Level
- XIN $2.75
- LPCN $3.57
- Average True Range (ATR)
- XIN 0.16
- LPCN 0.26
- MACD
- XIN -0.01
- LPCN -0.00
- Stochastic Oscillator
- XIN 31.58
- LPCN 23.29
About XIN Xinyuan Real Estate Co Ltd
Xinyuan Real Estate Co Ltd operates as a real estate developer and property manager in China. It focuses on developing residential projects, which typically consist of multiple residential buildings that include multi-layer apartment buildings, and others. Its several projects include auxiliary services and amenities such as retail outlets, leisure and health facilities, kindergartens, and schools. It aims to provide comfortable and convenient real estate-related products and services to middle-class consumers.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.